Actively Recruiting
Eltrombopag for Chemotherapy-induced Thrombocytopenia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-02-24
50
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
Sponsors
I
Institute of Hematology & Blood Diseases Hospital, China
Lead Sponsor
T
Tianjin Medical University Cancer Institute and Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of eltrombopag to treat chemotherapy-induced thrombocytopenia in solid tumors
CONDITIONS
Official Title
Eltrombopag for Chemotherapy-induced Thrombocytopenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older, male or female
- Diagnosed with chemotherapy-induced thrombocytopenia (CIT) with ineffective response after repeated treatment with rhTPO or IL-11
- Stopped radiotherapy or chemotherapy for more than 1 month
- Platelet counts below 30 x 10^9/L with bleeding tendency
- Estimated survival period of at least 6 months
- Willing to voluntarily sign informed consent and follow the study procedures
- Liver and kidney function less than 1.5 times the upper limit of normal and qualified for physical examination
- Using an acceptable method of contraception; women of childbearing potential must have a negative serum pregnancy test throughout the study
You will not qualify if you...
- Uncontrollable primary diseases of important organs such as extensive metastasis of malignant tumors, liver failure, heart failure, or kidney failure
- Poor compliance
- Positive for HIV, hepatitis B virus, hepatitis C virus, hepatitis D virus, or Syphilis; positive for Epstein-Barr Virus DNA or Cytomegalovirus DNA
- Extensive and severe bleeding such as hemoptysis, upper gastrointestinal bleeding, or intracranial hemorrhage
- Current heart disease requiring treatment or poorly controlled hypertension
- Thrombotic diseases including pulmonary embolism, thrombosis, or atherosclerosis
- History of allogeneic stem cell transplantation or organ transplantation
- Mental disorders preventing informed consent or proper trial participation
- Ongoing toxic symptoms from previous treatments
- Other serious diseases restricting participation (e.g., diabetes, severe heart failure, myocardial obstruction, unstable arrhythmia or angina, gastric ulcers, autoimmune diseases)
- Sepsis or irregular bleeding
- Concurrent use of antiplatelet drugs
- Pregnant, suspected pregnancy, or breastfeeding
- Pre-existing cardiac disease including severe heart failure (NYHA Grade III/IV), arrhythmia requiring treatment, or recent myocardial infarction
- Researchers' judgment that participation is not appropriate due to other conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese Academy of Medical Science and Blood Disease Hospital
Tianjin, Tianjin Municipality, China, 300020
Actively Recruiting
Research Team
Y
Yunfei Chen, MD
CONTACT
L
Lei Zhang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here